Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

CDC73-Related Disorders in Primary Hyperparathyroidism

Published: Fri, 23 Feb 2018 12:00:00 EST
This article provides insight into the clinical manifestations of CDC73-related disorders and discusses ways to improve case detection in primary hyperparathyroidism.
Journal of Clinical Endocrinology & Metabolism

Geogenomic Segregation and Temporal Trends of E. coli

Published: Fri, 23 Feb 2018 12:00:00 EST
A new report provides insight into the incidence and geographic segregation of Escherichia coli O157:H7 infections.
Emerging Infectious Diseases

FDA Alert: Clarithromycin Risky in Patients With Heart Disease

Published: Thu, 22 Feb 2018 17:33:59 EST
The agency adds a new warning about the increased risk for death in patients with heart disease prescribed the antibiotic clarithromycin and recommends considering an alternative when possible.
News Alerts

KDIGO Releases CKD-MBD Guidelines, Targets PCPs, Nephrologists

Published: Thu, 22 Feb 2018 16:52:07 EST
KDIGO released new guidelines on chronic kidney disease-mineral and bone disorder for nephrologists and primary care physicians, many of whom care for patients with chronic kidney disease themselves.
Medscape Medical News
Displaying results 9-12 (of 20)
 1 - 2 - 3 - 4 - 5 


Ipsen joins Arix’s growing pool of pharma partners

Published: Wed, 21 Feb 2018 13:11:36 +0000
Ipsen has become the latest drugmaker to start working with Arix Bioscience. The French biopharma follows Fosun, Takeda and UCB to become the fourth company to secure a connection to Arix’s stable of startups.

Merck inks $394M takeover of oncolytic virus play Viralytics

Published: Wed, 21 Feb 2018 10:47:21 +0000
Merck is set to pay $394 million to acquire Viralytics. The takeover will give Merck control of an oncolytic immunotherapy that Viralytics is testing in combination with Keytruda in early-phase trials.

Ionis farms out antisense drug to AstraZeneca in deal worth up to $330M

Published: Tue, 20 Feb 2018 15:25:40 +0000
Ionis Pharmaceuticals has licensed an antisense drug for the treatment of kidney disease to AstraZeneca, picking up a $30 million payment in the process.

Aimmune aces peanut allergy phase 3, teeing up FDA filing

Published: Tue, 20 Feb 2018 13:25:58 +0000
Aimmune has presented strong data from a phase 3 trial of its peanut allergy treatment AR101. The Brisbane, California-based biotech plans to file for FDA approval by the end of 2018 to give patients a way to protect themselves against accidental exposure to peanut protein.
Displaying results 9-12 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy